BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tiwari-Heckler S, Gan-Schreier H, Stremmel W, Chamulitrat W, Pathil A. Circulating Phospholipid Patterns in NAFLD Patients Associated with a Combination of Metabolic Risk Factors. Nutrients. 2018;10. [PMID: 29883377 DOI: 10.3390/nu10050649] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Ren F, Chen Q, Meng C, Chen H, Zhou Y, Zhang H, Chen W. Serum metabonomics revealed the mechanism of Ganoderma amboinense polysaccharides in preventing non-alcoholic fatty liver disease (NAFLD) induced by high-fat diet. Journal of Functional Foods 2021;82:104496. [DOI: 10.1016/j.jff.2021.104496] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
2 Schattenberg JM, Bergheim I. Nutritional Intake and the Risk for Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients 2019;11:E588. [PMID: 30862016 DOI: 10.3390/nu11030588] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
3 Guerra S, Mocciaro G, Gastaldelli A. "Adipose tissue insulin resistance and lipidome alterations are the characterizing factors of NASH". Eur J Clin Invest 2021;:e13695. [PMID: 34695228 DOI: 10.1111/eci.13695] [Reference Citation Analysis]
4 Niu L, Sulek K, Vasilopoulou CG, Santos A, Wewer Albrechtsen NJ, Rasmussen S, Meier F, Mann M. Defining NASH from a Multi-Omics Systems Biology Perspective. J Clin Med 2021;10:4673. [PMID: 34682795 DOI: 10.3390/jcm10204673] [Reference Citation Analysis]
5 Lüchtenborg C, Niederhaus B, Brügger B, Popovic B, Fricker G. Lipid Profiles of Five Essential Phospholipid Preparations for the Treatment of Nonalcoholic Fatty Liver Disease: A Comparative Study. Lipids 2020;55:271-8. [PMID: 32255515 DOI: 10.1002/lipd.12236] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Yamamoto Y, Sakurai T, Chen Z, Furukawa T, Gowda SGB, Wu Y, Nouso K, Fujii Y, Yoshikawa Y, Chiba H, Hui SP. Analysis of serum lysophosphatidylethanolamine levels in patients with non-alcoholic fatty liver disease by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 2021;413:245-54. [PMID: 33090255 DOI: 10.1007/s00216-020-02996-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kupčová V, Fedelešová M, Bulas J, Kozmonová P, Turecký L. Overview of the Pathogenesis, Genetic, and Non-Invasive Clinical, Biochemical, and Scoring Methods in the Assessment of NAFLD. Int J Environ Res Public Health 2019;16:E3570. [PMID: 31554274 DOI: 10.3390/ijerph16193570] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
8 Albhaisi S, Chowdhury A, Sanyal AJ. Non-alcoholic fatty liver disease in lean individuals. JHEP Rep 2019;1:329-41. [PMID: 32039383 DOI: 10.1016/j.jhepr.2019.08.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 9.3] [Reference Citation Analysis]
9 Schneider CV, Schneider KM, Conlon DM, Park J, Vujkovic M, Zandvakili I, Ko YA, Trautwein C, Center R, Carr RM, Strnad P, Thaiss CA, Rader DJ. A genome-first approach to mortality and metabolic phenotypes in MTARC1 p.Ala165Thr (rs2642438) heterozygotes and homozygotes. Med (N Y) 2021;2:851-863.e3. [PMID: 34258604 DOI: 10.1016/j.medj.2021.04.011] [Reference Citation Analysis]
10 Tung YT, Zeng JL, Ho ST, Xu JW, Li S, Wu JH. Anti-NAFLD Effect of Djulis Hull and Its Major Compound, Rutin, in Mice with High-Fat Diet (HFD)-Induced Obesity. Antioxidants (Basel) 2021;10:1694. [PMID: 34829565 DOI: 10.3390/antiox10111694] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Martins AMA, Garcia JHP, Eberlin MN. Mass Spectrometry as a Clinical Integrative Tool to Evaluate Hepatocellular Carcinoma: Moving to the Mainstream. Expert Rev Gastroenterol Hepatol 2019;13:821-5. [PMID: 31382786 DOI: 10.1080/17474124.2019.1651643] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Pfohl M, Ingram L, Marques E, Auclair A, Barlock B, Jamwal R, Anderson D, Cummings BS, Slitt AL. Perfluorooctanesulfonic Acid and Perfluorohexanesulfonic Acid Alter the Blood Lipidome and the Hepatic Proteome in a Murine Model of Diet-Induced Obesity. Toxicol Sci 2020;178:311-24. [PMID: 32991729 DOI: 10.1093/toxsci/kfaa148] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
13 Park S, Lee J, Lee SM, Lee J, Seo C, Hwang G, Jung J. An unbiased lipidomics approach identifies key lipid molecules as potential therapeutic targets of Dohongsamul-tang against non-alcoholic fatty liver diseases in a mouse model of obesity. Journal of Ethnopharmacology 2020;260:112999. [DOI: 10.1016/j.jep.2020.112999] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
14 Wu Y, Chen Z, Fuda H, Tsukui T, Wu X, Shen N, Saito N, Chiba H, Hui SP. Oxidative Stress Linked Organ Lipid Hydroperoxidation and Dysregulation in Mouse Model of Nonalcoholic Steatohepatitis: Revealed by Lipidomic Profiling of Liver and Kidney. Antioxidants (Basel) 2021;10:1602. [PMID: 34679736 DOI: 10.3390/antiox10101602] [Reference Citation Analysis]
15 Wang J, Zheng J, Ren X, Wang S, Wang G, Hu B, Yang H, Liu H. Integrative analysis of hepatic metabolomic and transcriptomic data reveals potential mechanism of nonalcoholic steatohepatitis in high-fat diet-fed mice. J Diabetes 2020. [PMID: 33022884 DOI: 10.1111/1753-0407.13120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
16 Draijer LG, Froon-Torenstra D, van Weeghel M, Vaz FM, Bohte AE, Holleboom AG, Benninga MA, Koot BGP. Lipidomics in Nonalcoholic Fatty Liver Disease: Exploring Serum Lipids as Biomarkers for Pediatric Nonalcoholic Fatty Liver Disease. J Pediatr Gastroenterol Nutr. 2020;71:433-439. [PMID: 32947564 DOI: 10.1097/mpg.0000000000002875] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
17 Vural H, Armutcu F, Akyol O, Weiskirchen R. The potential pathophysiological role of altered lipid metabolism and electronegative low-density lipoprotein (LDL) in non-alcoholic fatty liver disease and cardiovascular diseases. Clin Chim Acta 2021;523:374-9. [PMID: 34678296 DOI: 10.1016/j.cca.2021.10.018] [Reference Citation Analysis]
18 Montandon SA, Somm E, Loizides-Mangold U, de Vito C, Dibner C, Jornayvaz FR. Multi-technique comparison of atherogenic and MCD NASH models highlights changes in sphingolipid metabolism. Sci Rep. 2019;9:16810. [PMID: 31728041 DOI: 10.1038/s41598-019-53346-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
19 Gaskell H, Ge X, Desert R, Das S, Han H, Lantvit D, Guzman G, Nieto N. Ablation of Hmgb1 in Intestinal Epithelial Cells Causes Intestinal Lipid Accumulation and Reduces NASH in Mice. Hepatol Commun 2020;4:92-108. [PMID: 31909358 DOI: 10.1002/hep4.1448] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
20 Kartsoli S, Kostara CE, Tsimihodimos V, Bairaktari ET, Christodoulou DK. Lipidomics in non-alcoholic fatty liver disease. World J Hepatol 2020; 12(8): 436-450 [PMID: 32952872 DOI: 10.4254/wjh.v12.i8.436] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
21 Liu L, Zhao J, Zhang R, Wang X, Wang Y, Chen Y, Feng R. Serum untargeted metabolomics delineates the metabolic status in different subtypes of non-alcoholic fatty liver disease. J Pharm Biomed Anal 2021;200:114058. [PMID: 33865049 DOI: 10.1016/j.jpba.2021.114058] [Reference Citation Analysis]
22 Wu ZE, Fraser K, Kruger MC, Sequeira IR, Yip W, Lu LW, Plank LD, Murphy R, Cooper GJS, Martin JC, Hollingsworth KG, Poppitt SD. Untargeted metabolomics reveals plasma metabolites predictive of ectopic fat in pancreas and liver as assessed by magnetic resonance imaging: the TOFI_Asia study. Int J Obes (Lond) 2021;45:1844-54. [PMID: 33994541 DOI: 10.1038/s41366-021-00854-x] [Reference Citation Analysis]
23 Geng Y, Faber KN, de Meijer VE, Blokzijl H, Moshage H. How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease? Hepatol Int 2021;15:21-35. [PMID: 33548031 DOI: 10.1007/s12072-020-10121-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
24 Castañé H, Baiges-Gaya G, Hernández-Aguilera A, Rodríguez-Tomàs E, Fernández-Arroyo S, Herrero P, Delpino-Rius A, Canela N, Menendez JA, Camps J, Joven J. Coupling Machine Learning and Lipidomics as a Tool to Investigate Metabolic Dysfunction-Associated Fatty Liver Disease. A General Overview. Biomolecules 2021;11:473. [PMID: 33810079 DOI: 10.3390/biom11030473] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 He D, Su Y, Meng D, Wang X, Wang J, Ye H. A pilot study optimizing metabolomic and lipidomic acquisition in serum for biomarker discovery in nonalcoholic fatty liver disease. J Mass Spectrom Adv Clin Lab 2021;22:17-25. [PMID: 34939051 DOI: 10.1016/j.jmsacl.2021.10.001] [Reference Citation Analysis]
26 Mann JP, Pietzner M, Wittemans LB, Rolfe EL, Kerrison ND, Imamura F, Forouhi NG, Fauman E, Allison ME, Griffin JL, Koulman A, Wareham NJ, Langenberg C. Insights into genetic variants associated with NASH-fibrosis from metabolite profiling. Hum Mol Genet 2020;29:3451-63. [PMID: 32720691 DOI: 10.1093/hmg/ddaa162] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
27 Di Sessa A, Riccio S, Pirozzi E, Verde M, Passaro AP, Umano GR, Guarino S, Miraglia del Giudice E, Marzuillo P. Advances in paediatric nonalcoholic fatty liver disease: Role of lipidomics. World J Gastroenterol 2021; 27(25): 3815-3824 [PMID: 34321846 DOI: 10.3748/wjg.v27.i25.3815] [Reference Citation Analysis]
28 Yamamoto Y, Sakurai T, Chen Z, Inoue N, Chiba H, Hui S. Lysophosphatidylethanolamine Affects Lipid Accumulation and Metabolism in a Human Liver-Derived Cell Line. Nutrients 2022;14:579. [DOI: 10.3390/nu14030579] [Reference Citation Analysis]
29 Heintz MM, Kumar R, Maner-smith KM, Ortlund EA, Baldwin WS, Wertz PW. Age- and Diet-Dependent Changes in Hepatic Lipidomic Profiles of Phospholipids in Male Mice: Age Acceleration in Cyp2b-Null Mice. Journal of Lipids 2022;2022:1-17. [DOI: 10.1155/2022/7122738] [Reference Citation Analysis]
30 Bungau S, Behl T, Tit DM, Banica F, Bratu OG, Diaconu CC, Nistor-Cseppento CD, Bustea C, Aron RAC, Vesa CM. Interactions between leptin and insulin resistance in patients with prediabetes, with and without NAFLD. Exp Ther Med 2020;20:197. [PMID: 33123227 DOI: 10.3892/etm.2020.9327] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]